Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

GSK Biologicals gets rights to Abeta-targeting vaccines; terminated

Executive Summary

GlaxoSmithKline Biologicals has received exclusive development and marketing rights to Austrian biotech Affiris GMBH's two Phase I vaccines for Alzheimer's disease. The vaccines aim to remove amyloid beta (Abeta), which builds up in the brain of an AD patient to form amyloid plaques.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies

UsernamePublicRestriction

Register